Today: 18 March 2026
Subscribe
Browse Category

OTC:RNAZ.O 5 February 2026

TransCode Therapeutics stock jumps on FDA filing for Phase 2a colorectal cancer trial

TransCode Therapeutics stock jumps on FDA filing for Phase 2a colorectal cancer trial

TransCode Therapeutics shares surged nearly 19% Thursday after the company filed an amended IND application for a Phase 2a trial of TTX-MC138 in colorectal cancer patients. Trading volume hit 11.5 million shares, up from 8,500 the previous day. The dose-expansion study, set to begin in early 2026, will enroll up to 45 patients with positive ctDNA markers. The trial will run with Quantum Leap Healthcare Collaborative on the PRE-I-SPY platform.
5 February 2026
·

Stock Market Today

  • Ovid Therapeutics Q4 EPS and Revenue Beat Estimates, Shares Rally 23% in 2025
    March 18, 2026, 9:33 AM EDT. Ovid Therapeutics (OVID) reported Q4 adjusted earnings per share (EPS) of $0.06, surpassing the Zacks consensus estimate loss of $0.10 and reversing last year's $0.13 loss. Revenue jumped to $0.72 million, beating estimates by 195%, up from $0.08 million a year ago. The earnings surprise stands at +158.71%. Shares have risen 23.3% year-to-date, outperforming the S&P 500 which fell 1.9%. Despite the strong quarter, the Zacks Rank remains Hold at #3 due to mixed earnings estimate revisions ahead of the earnings call. Consensus anticipates EPS of -$0.08 and revenues of $0.2 million next quarter, signalling cautious investor sentiment amid industry risks in the Medical - Biomedical and Genetics sector.
Go toTop